Breaking News

Allergan to Share New Data at ARVO 2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May 1-7).
“We are excited to present a range of data that will help us better understand not just how our portfolio performs in the clinic, but also the real-world experiences of our patients,” said Michael R. Robinson, M.D., vice president, global therapeutic area head, eye care, AbbVie. “The diversity of our data at ARVO 2021 demonstrates how Allergan Eye Care is advancing potential treatments for patients living with a number of difficult-to-treat eye diseases including presbyopia and retina diseases such as age-related macular degeneration.”
The company will present patient-reported outcomes for AGN-190584, an investigational therapy for the treatment of presbyopia. Recently the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration based on data from the Phase 3 GEMINI 1 and GEMINI 2 clinical studies.
Data presented at the meeting will also include new analyses from the Phase 3 ARTEMIS studies examining the duration of intraocular pressure (IOP) lowering and biodegradation kinetics of DURYSTA™.
Additionally, real world data from the multicenter EXPAND study, evaluating 12-month outcomes of an investigation into a novel placement of the XEN® Gel Stent, will be presented at the meeting. The XEN® Gel Stent is currently approved only for ab-interno placement.
The ARVO 2021 Annual Virtual Meeting abstracts can be viewed at https://arvo2021.arvo.org/agenda.
Details about the presentations are as follows:
Abstract |
Presentation Details All Times EDT |
Glaucoma |
|
Extended Duration of IOP Lowering with Bimatoprost Implant in |
Paper session: Pharmacological intervention or Sunday, May 2 11:15 a.m. EDT |
A Minipump Continuous Drug Infusion Dog Model System to |
Poster session: Pharmacological intervention Monday, May 3 11:15 a.m. EDT |
Rate of Bimatoprost Implant Biodegradation in the Phase 3 |
Paper session: Clinical Studies Monday, May 3 11:15 a.m. EDT |
Corneal Endothelial Cell Loss Associated with Selective Laser |
Poster session: Ocular Blood Flow, Laser Wednesday, May 5 2:45 p.m. EDT |
A Retrospective Analysis: Visual Field Progression and Visual |
Poster session: Structure/Function, Visual Monday, May 3 4:30 p.m. EDT |
Retrospective, Multicenter, 12-month Evaluation of Ab-externo |
Poster session: Surgery and Wound Healing I Wednesday, May 5 9:00 a.m. EDT |
Presbyopia |
|
Evaluating Vision-related Reading Ability With a de Novo PRO |
Poster session: Refractive error, refraction, Thursday, May 6 11:15 a.m. EDT |
Assessing Presbyopia Impacts and Coping Behaviors with a de Novo PRO Instrument in a Phase 3 Study of AGN-190584 |
Poster session: Refractive error, refraction, Thursday, May 6 11:15 a.m. EDT |
Age-related Macular Degeneration |
|
Duration of Effect of a Single Intravitreal Injection of a |
Poster session: AMD and retinal physiology Wednesday, May 5 2:45 p.m. EDT |
Developing Methotrexate-induced Immune Tolerance in a |
Poster session: AMD and retinal physiology Wednesday, May 5 2:45 p.m. EDT |
Comparison of Visual Function in a Non-human Primate (NHP) |
Poster session: Psychophysics Friday, May 7 2:15 p.m. EDT |
Cytoprotective Effects of Brimonidine in an Induced Pluripotent |
Poster session: AMD and retinal physiology Wednesday, May 5 2:45 p.m. EDT |
Diabetic Macular Edema |
|
Profile of Vascular Permeability Factors in Aqueous Humor of |
Poster session: Diabetic macular edema Friday, May 7 2:15 p.m. EDT |
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more